Division of Basic Biomedical Sciences, University of South Dakota, 414 E Clark Street, Vermillion, SD 57069, USA.
Expert Rev Vaccines. 2014 Jan;13(1):31-42. doi: 10.1586/14760584.2014.852476.
Vaccination against influenza represents our most effective form of prevention. Historical approaches toward vaccine creation and production have yielded highly effective vaccines that are safe and immunogenic. Despite their effectiveness, these historical approaches do not allow for the incorporation of changes into the vaccine in a timely manner. In 2013, a recombinant protein-based vaccine that induces immunity toward the influenza virus hemagglutinin was approved for use in the USA. This vaccine represents the first approved vaccine formulation that does not require an influenza virus intermediate for production. This review presents a brief history of influenza vaccines, with insight into the potential future application of vaccines generated using recombinant technology.
接种流感疫苗是我们最有效的预防措施。在疫苗研发和生产方面，历史上的方法已经产生了高效、安全且具有免疫原性的疫苗。尽管这些方法效果显著，但它们无法及时将变化纳入疫苗中。2013 年，一种基于重组蛋白的流感病毒血凝素疫苗在美国获得批准使用。这种疫苗是第一种不需要流感病毒中间产物即可生产的批准疫苗。本文简要介绍了流感疫苗的历史，并探讨了使用重组技术生产的疫苗的潜在未来应用。
